Oxford Biomedica, one of the country’s leading biotechnology companies, is expanding its operations at Oxford Business Park.The company has completed a deal with the Park’s owner Arlington to take 11,390 sq ft of office space at Building 9400 on a 10-year lease.
The space will house the firm’s corporate team and is an addition to the 90,000sq ft Oxbox manufacturing facility which the business already occupies at the business park.
Yesterday this publication reported that Oxford Biomedica had secured a Certificate of GMP compliance for its fourth GMP manufacturing suite within the Group’s Oxbox manufacturing facility from the UK Medicines & Healthcare products Regulatory Agency (MHRA).
Nick Page, Chief Operating Officer of Oxford Biomedica said: “Oxford Business Park is already home to our manufacturing facility known as Oxbox, which is in operation for our viral vector manufacturing activities and also supporting the manufacture of a Covid-19 vaccine candidate. In March 2020, as our activities and workforce expanded, we took the decision to relocate our corporate headquarters team from our existing HQ to a new office location on the Park. Arlington have helpfully accommodated all of our commercial requirements with the new office and we are delighted with the quality of the building and the wider environment.”
Dan Williams, Development Director at Arlington’s Oxford Business Park, added: “Oxford Biomedica is at the forefront of the life science community in Oxford and recognised globally for their gene and cell therapies, and we are delighted to be able to help with their growth aspirations at the Park. As an existing customer of ours they are familiar with the high quality of our amenity rich environment and our customer focused approach and we look forward to continuing this exciting partnership with them for many years to come.”